Johanna C. Bendell

机构：Sarah Cannon, Tennessee Oncology · ORCID：0000-0001-9426-5891

发表论文 929 篇 · 总被引 31562 次 · h-index 83

代表论文

• Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study (2023 · The Lancet Oncology · 被引 259)
• First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors (2023 · Cancer Immunology Immunotherapy · 被引 125)
• Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors (2023 · JAMA Oncology · 被引 73)
• Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer (2023 · Nature Communications · 被引 41)
• Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors (2023 · British Journal of Cancer · 被引 35)
• Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer (2025 · Nature Communications · 被引 25)